Riot Platforms, Inc. quarterly report, Q1 FY2015

Filing identity and reporting period

The supplied filing is Venaxis, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015—not a filing identified as Riot Platforms, Inc. Investors should verify the issuer and filing period before relying on this summary.

Financial performance and liquidity

At March 31, 2015, cash and cash equivalents were $4.202 million and short-term investments were $17.902 million, totaling approximately $22.104 million in cash and liquid investments. Working capital was approximately $21.347 million. Total assets were $26.143 million, liabilities $4.211 million, and stockholders’ equity $21.932 million. Notes and other obligations totaled $2.177 million, including $218,401 current; the mortgage has a balloon maturity after five years. Cash increased $662,124 during the quarter, principally as net investment sales provided $3.083 million of investing cash inflow. No income tax benefit was recorded.

Changes and operating developments

Sales fell because 2015 minimum commitments for APPY 1 orders in Europe were lower. Management attributed lower SG&A partly to scaling back U.S. commercialization after an FDA determination in January 2015; R&D declined primarily after clinical trial activity ended in early 2014, partly offset by APPY 2 development. Investment income was $50,828 versus a $7,115 investment loss a year earlier. The share-based compensation expense was $433,402. Weighted-average shares rose to 30.99 million from 21.64 million, while reported loss per share narrowed to $0.07 from $0.14.

Outlook, risks, and contingencies

Management expects near-term operating losses, potentially significant, and said existing working capital should cover estimated needs into early 2016. The company was pursuing additional financing but gave no assurance it could obtain adequate funding on acceptable terms. Strategic priorities include evaluating regulatory and commercialization options for APPY 1, developing APPY 2, seeking partners or licensees, raising capital, and controlling costs. The company reported recurring losses and negative operating cash flow and stated the financial statements do not reflect adjustments that could be required if it cannot continue as a going concern.

Material uncertainties include FDA clearance and the ability to generate APPY 1 revenue; management cautioned that patent costs could be impaired if clearance or sufficient revenues are not achieved. A new securities class action alleges misleading statements about APPY 1, and a separate contract action alleges breach; the company considers both claims without merit and intends to defend them. The earlier Wolfe securities suit dismissal was affirmed on appeal. Animal-health licensing includes potential milestone payments of up to $1.1 million plus up to an additional $2 million for further products, as well as royalties, contingent on milestones and sales. Management reported no material changes to the risk factors in its 2014 Form 10-K.

Investor verification checklist

• Confirm the filing belongs to Venaxis, Inc. and is relevant to the intended issuer; it does not identify Riot Platforms, Inc.
• Review the January 2015 FDA determination and subsequent regulatory status and commercialization prospects for APPY 1.
• Track cash burn, financing efforts, and whether liquidity supports operations beyond management’s stated early-2016 estimate.
• Assess developments and potential exposure from the Boldt securities action and Bealer contract dispute.
• Verify the mortgage balloon terms, debt maturities, and any contingent animal-health license milestones or royalties.